Delayed Development of Coronary Artery Dilatation in Suspected Severe Acute Respiratory Syndrome Coronavirus 2 Multisystem Inflammatory Syndrome: More Research Needed

William B. Orr, MD; Alexis M. Elward, MD; John C. Lin, MD; Patrick J. Reich, MD, MSCI; Janet N. Scheel, MD; Ericka V. Hayes, MD; Kenneth E. Remy, MD, MHSc, MSCI, FCCM

Background: Although significant disease burden in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has been relatively uncommon in children, worldwide cases of a postinfectious multisystem inflammatory syndrome in children and possible atypical Kawasaki-like disease attributing to severe acute respiratory syndrome coronavirus 2 infection have arisen. Original thinking for coronavirus disease-19 disease was that an overwhelming proinflammatory response drove disease pathogenesis. Emerging reports suggest that a robust immune suppression may be more relevant and predominant. Recently reported data on children with multisystem inflammatory syndrome in children have demonstrated a heterogeneity of immune phenotypes among these patients, with concern for a strong initial proinflammatory state; however, data are lacking to support this. Likewise, understanding development of certain clinical findings to changes in the immune system is lacking.

Case Summary: We report a 12-year-old multiracial male with negative coronavirus disease-19 nasopharyngeal RNA polymerase chain reaction testing but positive severe acute respiratory syndrome coronavirus 2 serology, subsequent development of vasodilatory shock with myocardial depression, and subsequent delayed development of coronary artery dilatation after resolution of myocardial depression. Unlike previous reported cases of multisystem inflammatory syndrome in children, he exhibited profound lymphopenia without specific inflammatory cytokines elevations, whereas nonspecific markers (ferritin and C-reactive protein) were increased. He subsequently was discharged on day 12 of hospitalization with complete recovery.

Conclusion: Our representative case of a patient with coronavirus disease-19-associated multisystem inflammatory syndrome in children without robust hyperinflammation and a delayed finding of coronary artery dilatation compared with reported case series highlights the need for further mechanistic understanding of coronavirus disease-19 disease and subsequent multisystem inflammatory syndrome in children or Kawasaki disease development. This report offers a number of disease mechanisms and clinical evolution considerations for further elucidation to guide development of potential therapies.

Key Words: coronavirus disease-19; immune suppression; Kawasaki disease; multisystem inflammatory syndrome in children; research
atypical Kawasaki-like disease attributed to SARS-CoV-2 infection have arisen (8–10).

Preliminary evidence and hypotheses suggested that COVID-19 disease pathogenesis was driven by an overwhelming hyperinflammatory response. More recent emerging reports suggest that a robust immune suppression may be more relevant and predominant (11–13). Recently reported data on children with MIS-C have demonstrated a heterogeneity of immune phenotypes among these patients, with concern for a strong initial hyperinflammatory state; however, data are lacking to support this. In these reported cases and in our own experiences with a case of MIS-C with delayed development of an atypical Kawasaki-like disease, a number of questions have been developed.

A 12-year-old, previously healthy, fully immunized, multiracial male presented to our quaternary-care hospital after 1 week of fever and diarrhea. A nasopharyngeal COVID-19 RNA polymerase chain reaction was negative three times, and the serology of both parents was positive for SARS-CoV-2 immunoglobulin. A nasopharyngeal COVID-19 RNA polymerase chain reaction was negative three times, and the serology of both parents was positive for SARS-CoV-2 immunoglobulin.

At admission, he had hadosilatory septic shock with multiple laboratory and cardiac abnormalities including profound lymphopenia (absolute lymphocyte count [ALC] 392), thrombocytopenia (nadir 57), hyponatremia, hypophosphatemia, and fever (Table 1). During his 11 day ICU course, he received empiric broad-spectrum antibiotics, hemodynamic support for catecholamine-resistant septic shock, stress dose hydrocortisone for critical illness-related corticosteroid insufficiency (two doses), and high-flow cannula with subsequent noninvasive bilevel positive airway pressure support without the need for intubation. Cardiac specific evaluation showed initial electrocardiogram findings with prolonged corrected QT interval, transthoracic echocardiogram (TTE) showed borderline left ventricle ejection fraction with dyskinetic septum, and probrin natriuretic peptide (BNP) and troponin-I were both significantly elevated (Table 1). By days 4–6, an SARS-CoV-2 IgG test was positive, he became hypertensive requiring a nitroprusside infusion and subsequent transition to lisinopril, and his left ventricular ejection fraction decreased to 50%. An initial cytokine panel demonstrated tumor necrosis factor (TNF)-α, interferon (IFN)-γ, and interleukin (IL)-6 levels below the limit of detection and elevated IL-2R and IL-10 (Table 2). All other cytokines were within normal limits. His nonspecific inflammatory markers all normalized including p-dimer, ferritin, C-reactive protein (CRP), and fibrinogen, and he defervesced. At day 11, a predischarge TTE revealed normal systolic function, but his left main coronary artery, left anterior descending artery, circumflex artery, and right coronary artery (RCA) were all diffusely dilated with the RCA demonstrating the greatest amount of dilation with a fusiform appearing aneurysm and proximal RCA stenosis. He was discharged on low-dose aspirin and clopidogrel with a presumed diagnosis of COVID-19 MIS-C and atypical Kawasaki-like disease. A 4-week postdischarge TTE continued to have normal systolic function with unchanged coronary artery dilation and a slightly elevated troponin-I of 0.18 ng/mL. Anticoagulation therapy was continued and antihypertensive medications stopped after normalization of blood pressure.

Recent U.S. and U.K. reports of over 500 MIS-C patients have shown findings of lymphopenia, elevated CRP, ferritin, BNP, p-dimer, IL-6, and fibrinogen (8, 10, 14, 15). However, unlike these case series, our patient had much higher nonspecific inflammatory markers (CRP, ferritin, p-dimer, and fibrinogen) without elevation in IL-6 or TNF-α cytokine levels. Previous reports have demonstrated lymphopenia between 1,000 and 2,000 cells/mm². In contrast, our patient had an ALC less than 400, a finding similar to that seen in AIDS. Our patient’s divergent findings of elevation of some hyperinflammatory markers and depression of others highlight the presence of differing innate and adaptive immune phenotypes. In turn, this questions whether reported descriptive immune findings in adults can be accurately ascribed to children when children are presenting with different clinical manifestations over an altered time course. Likewise, prior to uniform pediatric use of therapies that have been attempted in adults, we must gain better understanding of key mechanistic pathways of SARS-CoV-2 infection and extrapolate and apply known pathologic mechanisms in other similar and previously elucidated diseases (e.g., known Kawasaki disease [KD] findings and other viruses).

Current COVID-19-induced Kawasaki-like disease may have overlapping mechanisms with canonical KD or may represent a completely different disease with overlapping clinical findings. Comparing the clinical and laboratory characteristics of these two entities has very distinct properties. From a clinical standpoint, patients with MIS-C have a broader age range with a median of 9 years, whereas KD patients have a narrower age range with a median of 2 years (8, 16). Patients with MIS-C also have a lower prevalence of developing the classic KD findings of conjunctivitis, rash, mucositis, extremity swelling, and cervical lymphadenopathy (16). Interestingly, it has been reported that patients with MIS-C compared with COVID-19-associated KD have lower WBC counts, worsened thrombocytopenia and lymphopenia, and decreased erythrocyte sedimentation rates with less anemia (higher hemoglobin values) (16). Our patient demonstrated more severe lymphopenia than previously reported and yet had hematologic findings that bridged both previously reported findings in MIS-C and KD (i.e., higher WBC counts with thrombocytopenia and anemia). Additionally, our patient developed coronary artery dilatation 11 days after acute presentation and after recovery of myocardial function. This novel finding has not been reported in case series that have focused on cardiac manifestations of MIS-C (17). This further delineates MIS-C and KD as heterogeneous syndromes with potentially differing subphenotypes.

Furthermore, canonical KD has previously demonstrated coronary vascular infiltration of neutrophils, cluster of differentiation 8 T lymphocytes, immunoglobulin-A-producing plasma cells, macrophages, and eosinophils (18–20). Numerous reports in adult COVID-19 disease have demonstrated isolated proinflammatory marker elevations but likely predominant immune suppression with T cell exhaustion and significant peripheral lymphopenia (11–13). Based on preliminary concerns of a hyperinflammatory state driving disease progression, many patients with MIS-C are treated with anti-inflammatory agents (corticosteroids, anakinra, and nonsteroidal anti-inflammatory drugs) (14, 15, 21, 22). However, if children demonstrate similar findings as in adults.
|                          | First Emergency Department Visit | Hospital Day 1 | Hospital Day 2 | Hospital Day 3 | Hospital Day 4 | Hospital Day 7 | Hospital Day 11 | 4-wk Postdischarge Follow-Up |
|--------------------------|----------------------------------|---------------|---------------|---------------|---------------|---------------|-----------------|-------------------------------|
| **Maximum temp**         | 37.7                             | 40.5          | 40.4          | 39            | 37.4          | 37.4          | 36.7            | 36.6                          |
| **Coronavirus disease 2019 polymerase chain reaction** | Negative\(^a\) | Negative\(^a\) | Negative\(^b\) |               |               |               |                 |                               |
| **Severe acute respiratory syndrome coronavirus 2 immunoglobulin-G** |                              |               |               |               |               |               |                 |                               |
| **WBC (K/cumm)**         | 7.0                              | 9.5           | 15.4          | 14.3          | 12.9          | 8.0           | 7.0             |                               |
| **Absolute lymphocyte count (cells/mm\(^3\))** | 392                             | 523           |               | 2,302         | 1,238         | 1,504         | 2,240           |                               |
| **Hemoglobin (g/dL)**    | 11.8                             | 12.0          | 10.5          | 9.8           | 9.0           | 8.8           | 11.8            |                               |
| **Platelet Count (K/cumm)** | 148                             | 57            | 85            | 89            | 81            | 191           | 468             |                               |
| **Sodium (mmol/L)**      | 126                              | 123           | 130           | 139           | 147           | 137           | 138             |                               |
| **Potassium (mmol/L)**   | 3.5                              | 3.0           | 2.2           | 3.3           | 3.5           | 3.4           | 3.8             |                               |
| **Phosphorus (mg/dL)**   | 2.0                              | 1.9           | 2.3           | 1.5           | 3.3           |               |                 |                               |
| **Blood urea nitrogen (mg/dL)** | 12                             | 49            | 29            | 11            | 10            | 9             | 7               |                               |
| **Creatinine (mg/dL)**   | 0.74                             | 2.04          | 1.31          | 0.75          | 0.72          | 0.58          | 0.52            |                               |
| **Alanine aminotransferase (Units/L)** | 11                             | 27            | 23            | 21            | 24            | 46            | 55              | 16                           |
| **Erythrocyte sedimentation rate (mm/hr)** | 30                             |               |               |               |               |               | 28              | 9                            |
| **C-reactive protein (mg/L)** | 137.4                          | 325.0         | 57.5          |               |               |               | 8.7             | 1                            |
| **Ferritin (ng/mL)**     | 2,758                            | 3,095         | 3,764         | 3,685         | 583           |               |                 |                               |
| **Fibrinogen (mg/dL)**   | 659                              | 589           | 463           | 295           |               |               |                 |                               |
| **d-dimer (ng/mL FEU)**  | 1,780                            | 1,636         | 957           | 1,060         | 749           |               |                 |                               |
| **Peak lactate (mmol/L)** | 1.8                             | 2.7           | 3.0           | 3.1           | 1.3           |               |                 |                               |
| **Troponin-I (ng/mL)**   | 0.64                             | 0.14          | 0.08          | 0.03          | 0.18          |               |                 |                               |
| **N-terminal pro hormone brain natriuretic peptide (pg/mL)** | 29,765                         | 22,613        | 13,495        | 5,528         | 200           |               |                 |                               |
| **Corrected QT interval on electrocardiogram** | 394                            | 475           | 470           | 446           | 462           | 430           |                 |                               |
| **Systolic function**    | SF 24.77% and EF 42.59%          | SF 22.56% and EF 39.48% |             |               |               |               | SF 29.62% and EF 48.03% | SF 33.99% and EF 55.05%     |
| **Coronary arteries**    | Normal                           | Normal        |               |               |               |               | Dilated LCA, LAD, circumflex, and RCA | Dilated LCA, LAD, circumflex, and RCA |

\(^a\)Coronavirus disease-19 RNA nasopharyngeal.

\(^b\)Coronavirus disease-19 RNA sputum.

\(^c\)Severe acute respiratory syndrome coronavirus 2 (coronavirus disease-19) antibody immunoglobulin-G.

Boldface represent abnormal values.
with immune suppression, these agents may have negative effects including the potential for development of secondary infections and/or unmitigated viral tissue replication. It is unclear how this may affect development from acute disease to MIS-C or KD.

Thus, a number of considerations remain regarding the broad definition of this syndrome, mechanisms involved, and the need for targeted rather than nonspecific therapies. This underscores a need for future studies in children to better characterize alterations in innate and adaptive immune functions not solely in acute infectious disease presentation but also in disease evolution to postinflammatory syndrome. Our case describes a patient that meets Centers for Disease Control and Prevention criteria for MIS-C with evolution of delayed KD findings of coronary artery dilations. A number of questions thus arise as follows:

- What mechanistically could describe findings of MIS-C at presentation and yet delayed findings of KD with coronary artery dilatation after four echocardiograms that have not been previously reported in large case series?
- When and how often should echocardiogram surveillance occur with children that meet MIS-C criteria at admission but may not have evidence of KD?
- Why in this illustrative case do we see a clinical presentation of vasodilatory shock with increased nonspecific inflammatory biomarkers and an absence of a “cytokine storm” of IL-6, TNF-α, or related proinflammatory cytokines but with profound lymphopenia and reduction in IFN-γ demonstrating immune exhaustion? Could changes in IL-2R be more relevant than IL-6 and provide further insight into JAK1, JAK3, or other tyrosine kinase/map kinase signaling pathways?
- With oversampling of diagnostic testing including serial echocardiograms, are we unearthing a phenomenon restricted only to SARS-CoV-2 virus or would other common childhood viruses with the same testing reveal similar findings?
- Recent data suggest that children less than 10 years old have diminished nasal gene expression of angiotensin-converting enzyme 2 (ACE-2) compared with greater than 10 year olds (23). Does this age-related increase in ACE-2 expression play a role in the observation that KD-like disease in SARS-CoV-2 infection occurs more frequently in an older population compared with KD and what other potential signaling pathways may be involved?
- Would the well-established ability of other coronaviruses to block type I and type III IFN responses provide further insights in additional therapies that may influence Janus kinases-STAT pathways? Could further elucidation of these pathways demonstrate more refined targeted therapies with improved outcomes for this syndrome or previously described canonical KD?

Presently, our understanding of MIS-C is limited to associations temporal to the COVID-19 disease. Better elucidation of relevant signaling pathways that define transition from acute disease to MIS-C is not only important for COVID-19 disease but may provide insights into understanding KD associated with other pathogens. Further evaluation of these considerations and questions could present many avenues for further investigation.

**REFERENCES**

1. Hasan A, Mehmood N, Fergie J: Coronavirus disease (COVID-19) and pediatric patients: A review of epidemiology, symptomatology, laboratory and imaging results to guide the development of a management algorithm. *Cureus* 2020; 12:e7485
2. Hong H, Wang Y, Chung HT, et al: Clinical characteristics of novel coronavirus disease 2019 (COVID-19) in newborns, infants and children. *Pediatr Neonatol* 2020; 61:131–132
3. Sinha IP, Harwood R, Semple MG, et al: COVID-19 infection in children. *Lancet Respir Med* 2020; 8:446–447
4. Tagarro A, Epalza C, Santos M, et al: Screening and severity of coronavirus disease 2019 (COVID-19) in children in Madrid, Spain. *JAMA Pediatr* 2020 Apr 8. [online ahead of print]
5. Team CC-R: Coronavirus disease 2019 in children - United States, February 12-April 2, 2020. *MMWR Morb Mortal Wkly Rep* 2020; 69:422–426

**TABLE 2. Cytokine Panel Obtained on Hospital Day 4**

| Cytokine                          | Result | Reference Value |
|-----------------------------------|--------|-----------------|
| Tumor necrosis factor-α (pg/mL)   | 5 (nmL)| ≤ 22            |
| IL-2 (pg/mL)                      | 9 (nmL)| ≤ 12            |
| IL-2R (pg/mL)                     | 17,370 (high)| ≤ 1,033        |
| IL-4 (pg/mL)                      | < 5 (nmL)| ≤ 5            |
| IL-5 (pg/mL)                      | < 5 (nmL)| ≤ 5            |
| IL-6 (pg/mL)                      | 6 (equivocal)| ≤ 5          |
| IL-8 (pg/mL)                      | < 5 (nmL)| ≤ 5            |
| IL-12 (pg/mL)                     | < 5 (nmL)| ≤ 6            |
| Interferon-γ (pg/mL)              | < 5 (nmL)| ≤ 5            |
| IL-10 (pg/mL)                     | 122 (high)| ≤ 18          |
| IL-13 (pg/mL)                     | < 5 (nmL)| ≤ 5            |
| IL-17 (pg/mL)                     | 11 (nmL)| ≤ 11           |
| IL-1β (pg/mL)                     | < 5 (nmL)| ≤ 36           |

IL = interleukin. Boldface represent abnormal values.

Invariably, many children will present with SARS-CoV-2 positive antibody serology testing in the fall with signs and symptoms consistent with sepsis, hemophagocytic lymphohistiocytosis, or MIS-C; differentiating between these entities diagnostically and with subsequent therapies will be important in patient management and potential outcomes.

**ACKNOWLEDGMENTS**

We thank our patient and his family who provided consent for this report and to the Washington University in St. Louis Institutional Review Board that who waived review with exempted approval.

For information regarding this article, E-mail: kremy@wustl.edu
6. Shekerdemian LS, Mahmood NR, Wolfe KK, et al: Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian pediatric intensive care units. *JAMA Pediatr* 2020 May 11. [online ahead of print]

7. Yonker LM, Shen K, Kinane TB: Lessons unfolding from pediatric cases of COVID-19 disease caused by SARS-CoV-2 infection. *Pediatr Pulmonol* 2020; 55:1085–1086

8. Cheung EW, Zachariah P, Gorelik M, et al: Multisystem inflammatory syndrome related to COVID-19 in previously healthy children and adolescents in New York City. *JAMA* 2020; 324:294–296

9. Miller J, Cantor A, Zachariah P: Gastrointestinal symptoms as a major presentation component of a novel multisystem inflammatory syndrome in children (MIS-C) that is related to COVID-19: A single center experience of 44 cases. *Gastroenterol* 2020 Jun 4. [online ahead of print]

10. Whittaker E, Bamford A, Kenny J, et al; PIMS-TS Study Group and EUCLIDS and PERFORM Consortia: Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. *JAMA* 2020; 324:259–269

11. Remy KE, Brakenridge SC, Francois B, et al: Immunotherapies for COVID-19: Lessons learned from sepsis. *Lancet Respir Med* 2020 Apr 28. [online ahead of print]

12. Mudd PA, Crawford JC, Turner JS, et al: Targeted immunosuppression distinguishes COVID-19 from influenza in moderate and severe disease. *medRxiv* 2020.05.28.20115667

13. Remy KE, Mazer M, David A, et al: Severe immune suppression and not a “cytokine storm” characterize COVID-19 infections. *JCI Insight* 2020; 5:140329

14. Dufort EM, Koumans EH, Chow EJ, et al: Multisystem inflammatory syndrome in children in New York State. *N Engl J Med* 2020; 383:347–358

15. Feldstein LR, Rose EB, Horwitz SM, et al: Multisystem inflammatory syndrome in U.S. children and adolescents. *N Engl J Med* 2020; 383:334–346

16. Lee PY, Day-Lewis M, Henderson LA, et al: Distinct clinical and immunological features of SARS-CoV-2-induced multisystem inflammatory syndrome in children. *J Clin Invest* 2020 Jul 23:141113. [online ahead of print]

17. Capone CA, Subramony A, Sweberg T, et al: Characteristics, cardiac involvement, and outcomes of multisystem inflammatory disease of childhood (MIS-C) associated with SARS-CoV-2 infection. *J Pediatr* 2020; 224:141–145

18. Kumrah R, Vignesh P, Rawat A, et al: Immunogenetics of Kawasaki disease. *Clin Rev Allergy Immunol* 2020; 59:122–139

19. McCrindle BW, Rowley AH, Newburger JW, et al: American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; and Council on Epidemiology and Prevention: Diagnosis, treatment, and long-term management of Kawasaki disease: A scientific statement for health professionals from the American Heart Association. *Circulation* 2017; 135:e927–e999

20. Noval Rivas M, Arditi M: Kawasaki disease: Pathophysiology and insights from mouse models. *Nat Rev Rheumatol* 2020; 16:391–405

21. Feldstein LR, Rose EB, Horwitz SM, et al: Multisystem inflammatory syndrome in US children and adolescents. *N Engl J Med* 2020; 383:334–346

22. Pontali E, Volpi S, Antonucci G, et al: Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease. *J Allergy Clin Immunol* 2020; 146:213–215

23. Bunyavanich S, Do A, Vicencio A: Nasal gene expression of angiotensin-converting enzyme 2 in children and adults. *JAMA* 2020; 323:2427–2429